Nombre del producto:ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate

IUPAC Name:ethyl 2,4-dimethyl-1H-pyrrole-3-carboxylate

CAS:2199-51-1
Fórmula molecular:C9H13NO2
Pureza:95%+
Número de catálogo:CM103853
Peso molecular:167.21

Unidad de embalaje Stock disponible Precio($) Cantidad
CM103853-25g in stock ƼDz
CM103853-100g in stock ſȌȌ
CM103853-500g in stock ȌƋƤƤ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :2199-51-1
Fórmula molecular:C9H13NO2
Punto de fusión:-
Código de sonrisas:CCOC(=O)C1=C(C)NC=C1C
Densidad:
Número de catálogo:CM103853
Peso molecular:167.21
Punto de ebullición:291°C at 760 mmHg
Nº Mdl:MFCD01365811
Almacenamiento:Store at room temperature

Category Infos

Pyrroles
Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.
Pyrrole,Where to Buy Pyrroles-Chemenu
Pyrrole,Where to Buy Pyrroles
Pyrrole is a heterocyclic, aromatic, organic compound, a five-membered ring with the formula C 4H 4NH. It is a colorless volatile liquid that darkens readily upon exposure to air. Substituted derivatives are also called pyrroles, e.g., N-methylpyrrole.

Column Infos

Vorolanib
EyePoint Pharmaceuticals announced on December 4th announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E™. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor blocker, blocking all VEGF isoforms. Vorolanib features reduced off-target binding and at clinically relevant doses does not inhibit Tie-2, a critical pathway associated with vascular stability, which may result in an improved efficacy. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection, and potential antifibrotic benefits.